Recruiting studies: Aqp4 Nmosd

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

Monoclonal Antibody-Based Therapies for AQP4-Positive NMOSD
Phase N/A · 1 location(s) · Tongji Hospital · NCT06885957 Clinical Study of B001 Injection in Subjects With Neuromyelitis Optic Spectrum Disorder (NMOSD)
EARLY_Phase 1 · 4 location(s) · Shanghai Pharmaceuticals Holding Co., Ltd · NCT05145361 Registry of Patients With AQP4+ NMOSD Treated With Alexion C5 Inhibitor Therapies
Phase N/A · 33 location(s) · Alexion Pharmaceuticals, Inc. · NCT05966467 Ofatumumab in AQP4-IgG Seropositive NMOSD
Phase 1/Phase 2 · 1 location(s) · Tang-Du Hospital · NCT05504694 Modified Zipper Therapy for AQP4-IgG Positive Neuromyelitis Optica Spectrum Disorder
Phase 3 · 1 location(s) · Tianjin Medical University General Hospital · NCT07420296 Therapy in the Acute Phase of NMOSD: A Multicenter Prospective Real-World Study
Phase 4 · 1 location(s) · Chinese PLA General Hospital · NCT07410039 A Study To Evaluate Pharmacokinetics, Efficacy, Safety, Tolerability, And Pharmacodynamics Of Satralizumab In Pediatric
Phase 3 · 13 location(s) · Hoffmann-La Roche · NCT05199688

Look up another condition

Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.